The effectiveness and sustainability of health outcomes from an advanced digital weight-loss programme in the UK

Not Applicable

• Conditions: Overweight and obesity; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN14812004
• Lead Sponsor: Eucalyptus

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-27
• Last Update Posted: 10 June 2024
• Study Completion: 2025-10-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Between 18 years and 70 years of age at the time of completing the program’s pre-questionnaire
2. Satisfy the Medicines and Healthcare products Regulatory Agency (MHRA) guidelines for tirzepatide (Mounjaro) weight management
3. BMI of 30kg/m² or more (obesity), or a BMI between 27-30kg/m² (overweight) and also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems

Exclusion Criteria

1. Outside the 18-70 year age bracket
2. Does not have a BMI of 30 kg/m2 or more, or a BMI of 27-30 kg/m2 with at least one weight-related comorbidity such as pre-diabetes, high blood pressure, high cholesterol, heart problems
3. Has already started tirzepatide treatment as a current subscriber to the Eucalyptus weight-loss program
4. Failure to provide baseline measurements within three weeks of receiving confirmation of trial participation

Study & Design

• Study Type: Interventional
• Study Design: Not specified